Goldman Sachs: After the latest report following ASCO, we give CSPC Pharmaceutical Group (02616.HK) a "buy" rating with a target price of 9.44 HK dollars.

According to the Wisdom Financial APP, Goldman Sachs released a research report stating that it has given a "buy" rating to CSPC Pharmaceutical Group Limited-B (02616.HK), with a 12-month target price of HK$9.44 based on risk-adjusted DCF.